PrecisionLife Appoints New CCO

PrecisionLife, a trailblazer in precision medicine for complex chronic diseases, has appointed Bill Keating as its new Chief Commercial Officer for Diagnostics and Healthcare. Keating will lead the charge in bringing the company’s innovative Mechanostic® tests to the forefront of healthcare, aiming to predict, prevent, and personalize treatments for chronic diseases that affect billions of lives globally.

A Seasoned Leader in Precision Medicine

With over two decades of experience in senior leadership roles at industry-leading companies such as Philips Healthcare, Zephyr AI, and Foundation Medicine, Keating has a proven history of introducing transformative diagnostic solutions and achieving widespread market adoption. At PrecisionLife, he will focus on driving the commercialization of the company’s groundbreaking diagnostic tools and expanding their impact on patient care.

Revolutionizing Chronic Disease Management

PrecisionLife’s non-invasive, genotypic precision medicine tests are designed to identify individual risk factors and uncover the specific biological mechanisms driving complex diseases. These insights empower clinicians to:

• Predict and prevent disease progression
• Tailor treatment plans to each patient’s unique needs
• Improve the efficiency of clinical pathways and outcomes

By addressing the root causes of chronic diseases, these tests are paving the way for earlier interventions, more accurate diagnoses, and better patient outcomes—all while reducing inefficiencies in the healthcare system.

Bill Keating’s Excitement and Vision

Expressing his enthusiasm for the role, Keating shared:
"I’m thrilled to join PrecisionLife at this transformative moment. The company’s ability to deliver deep insights and predict risks across more than 50 chronic diseases is remarkable. By making personalized treatment recommendations a reality, we can have a profound impact on healthcare—helping to predict and prevent diseases, improve patient outcomes, and address inefficiencies from inaccurate referrals and ineffective treatments."

A Turning Point for PrecisionLife

Steve Gardner, CEO of PrecisionLife, welcomed Keating to the team, saying:
"We’re delighted to have Bill join us during this exciting period of growth. His expertise in scaling high-potential companies and his deep understanding of the diagnostics landscape make him the ideal person to drive our commercial strategy. With his leadership, we’ll be able to expand our innovative solutions globally, providing rapid, actionable insights for diseases that have long needed better diagnostic tools."

What’s Next?

Bill Keating’s appointment marks a new chapter for PrecisionLife as it accelerates efforts to reshape chronic disease care. With Keating at the helm of its commercial strategy, the company is well-positioned to create meaningful partnerships, improve healthcare efficiency, and, most importantly, transform the lives of millions of patients worldwide.